Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders.
Methods:
A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings by a panel of experts.
Results:
Recommendations identified covered a range of issues in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Further work in this area is warranted as we continue to further understand their presentation in the developing brain.
Conclusions:
Canadian guidelines for the pharmacotherapy management of children and youth with schizophrenia spectrum disorders are essential to assist clinicians in treating this vulnerable population. Ongoing work in this area is recommended.
RemingtonGAddingtonDHonerW. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616.
2.
National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Clinical guideline number155. 2013. [Cited 2016 November 15]. Available from: http://guidance.nice.org.uk/CG155.
3.
AddingtonDAbidiSGarcia-OrtegaI. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. Can J Psychiatry. 2017;62(9):594–603.
4.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. Arlington (VA): American Psychiatric Association; 2013.
5.
LachmanA. New developments in diagnosis and treatment update: schizophrenia/first episode psychosis in children and adolescents. J Child Adolesc Ment Health. 2014;26(2):109–124.
6.
ScottJChantDAndrewsG. Psychotic-like experiences in the general community: the correlates of CIDI psychosis screen items in an Australian sample. Psychol Med. 2006;36(2):231–238.
7.
SchimmelmannBGSchmidtSJCarbonM. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry. 2013;26(2):219–230.
8.
CorrellCUKishimotoTNielsenJ. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16–B39.
9.
CorrellCUHauserMAutherAM. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51(4):390–431.
10.
LaurensKRCullenAE. Toward earlier identification and preventative intervention in schizophrenia: evidence from the London child health and development study. Soc Psychiatry Psychiatr Epidemiol. 2016;51(4):475–491.
11.
AddingtonJAddingtonDAbidiS. Canadian treatment guidelines for individuals at clinical high risk of psychosis. Can J Psychiatry. 2017;62(9):656–662.
12.
ChambersWJPuig-AntichJHirschM. The assessment of affective disorders in children and adolescents by semistructured interview: test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry. 1985;42(7):696–702.
13.
KaufmanJBirmaherBBrentD. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child and Adol Psych. 1997;36: 980–988.
14.
GillbergC. Schizophrenia in children and adolescents. In: RemischmidtH, editor. Epidemiology of early onset schizophrenia. Cambridge (GB): Cambridge University Press; 2001. p 43–59.
15.
ThomsenPH. Schizophrenia with childhood and adolescent onset: a nationwide register-based study. Acta Psychiatr Scand. 1996;94(3):187–193.
16.
BrownSKimMMitchellC. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2):116–121.
17.
HawtonKSuttonLHawC. Schizophrenia and suicide: a systematic review of risk factors. Br J Psychiatry. 2005;187(1):9–20.
18.
ClemmensenLVernalDLSteinhausenHC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150.
19.
AmmingerGPHenryLPHarriganSM. Outcome in early-onset schizophrenia revisited: findings from the early psychosis prevention and intervention centre long-term follow-up study. Schizophr Res. 2011;131(1):112–119.
20.
StaffordMRJacksonHMayo-WilsonE. Early interventions to prevent psychosis: systematic review and meta-analysis. Br Med J. 2013;346:f185.
21.
LecomteTAbidiSGarcia-OrtegaI. Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth. Can J Psychiatry. 2017;62(9):648–655.
22.
ADAPTE. The ADAPTE process: resource toolkit for guideline adaptation. Version 2.0. [Cited 2017 February 2]. Available from: http://www.g-i-n.net2009.
23.
BrouwersMKhoMEBrowmanGP. AGREE II: advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 2010;2010(182):E839–E842.
24.
SouaibyLGaillardRKrebsMO. Duration of untreated psychosis: a state-of-the-art review and critical analysis. Encephale. 2016;42(4):361–366.
25.
FraguasDDel Rey-MejíasAMorenoC. Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study. Schizophr Res. 2014;52(1):130–138.
26.
FraguasDMerchán-NaranjoJdel Rey-MejíasÁ. A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. Schizophr Res. 2014;158(1–3):126–133.
27.
Stentebjerg-OlesenMPagsbergAKFink-JensenA. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol. 2016;26(5):410–427.
28.
MarkulevCMcGorryPDNelsonB. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv Psychiatry. Epub 2015 Aug 16. doi:10.1111/eip.12260.
29.
AmmingerGPSchäferMRSchlögelhoferM. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934.
30.
MarinoLNosselIChoiJC. The RAISE connection program for early psychosis: secondary outcomes and mediators and moderators of improvement. J Nerv Ment Dis. 2015;203(5):365–371.
31.
Fusar-PoliPDíaz-CanejaCMPatelR. Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatr Scand. 2016;133(1):76–85.
32.
BroussardBKelleyMEWanCR. Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res. 2013;148(1–3):93–98.
33.
KarangesEAStephensonCPMcGregorIS. Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: focus on children, adolescents and prescriber specialty. Aust N Z J Psychiatry. 2014;48(10):917–931.
34.
CartonLCottencinOLapeyre-MestreM. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–3297.
35.
BachmannCJLemppTGlaeskeG. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch Arztebl Int. 2014;111(3):25–34.
36.
PenfoldRBStewartCHunkelerEM. Use of antipsychotic medications in pediatric populations: what do the data say?Curr Psychiatry Rep. 2013;15(12):1–10.
37.
MarstonLNazarethIPetersenI. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4(12):e006135.
38.
LeeHEJureidiniJ. Emerging psychosis in adolescents: a practical guide. Aust Fam Physician. 2013;42(9):624–627.
39.
HollisC. Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry. 2000;157(10):1652–1659.
40.
JoaIJohannessenJOLangeveldJ. Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. Acta Psychiatr Scand. 2009;119(6):494–500.
41.
CorrellCUKratochvilCJMarchJS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72(5):655–670.
42.
CorrellCURobinsonDGSchoolerNR. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–1363.
43.
VyasNSPatelNHPuriBK. Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry. 2011;5(1):3–14.
44.
ReichertAKreikerSMehler-WexC. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health. 2008;2(1):6.
45.
CorrellCU. Antipsychotic agents: typical and atypical. In: MartinAScahillLKratochvilCJ. Editors. Pediatric Psychopharmacology: principles and practice. 2nd ed. New York (NY): Oxford University Press; 2011. p 312–337.
46.
CorrellCU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12–S21.
47.
National Institute for Health and Care Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Clinical guideline number82. 2009. [Cited 2016 February 15]. Avialable fromhttps://www.nice.org.uk/guidance/cg82
48.
JohansenRIversenVCMelleI. Therapeutic alliance in early schizophrenia spectrum disorders: a cross-sectional study. Ann Gen Psychiatry. 2013;12(1):14.
49.
PriebeSRichardsonMCooneyM. Does the therapeutic relationship predict outcomes of psychiatric treatment in patients with psychosis? A systematic review. Psychother Psychosom. 2011;80(2):70–77.
50.
ThomaPDaumI. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013;67:367–338.
51.
SaraGELargeMMMathesonSL. Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust N Z J Psychiatry. 2015;49(2):106–117.
VegaWAAguilar-GaxiolaSAndradeL. Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology. Drug Alcohol Depend. 2002;68(3):285–297.
54.
World Health Organization. Young people’s health in context: Health Behavior in School-Aged Children (HBSC) study. International report from the 2001-2002 survey. In: CurrieRobertsCMorganCSmithASettertobulteRSamdalWBarnekow RasmussenOV, editors. Geneva (CH): World Health Organization; 2004. p 248.
55.
FergussonDMHorwoodLJSwain-CampbellNR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15–21.
56.
RadhakrishnanRWilkinsonSTD’SouzaDC. Gone to pot: a review of the association between cannabis and psychosis. Front Psychiatry. 2014;5:54.
57.
OlivaresJMSermonJHemelsM. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.
58.
DavisJEyreHJackaFN. A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev. 2016;65:185–194.
59.
HallW. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?Addiction. 2015;110(1):19–35.
60.
MonteleonePDi FilippoCFabrazzoM. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res. 2014;215(2):263–267.
61.
DonoghueKDoodyGAMurrayRM. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014;215(3):528–532.
62.
MalchowBHasanASchneider-AxmannT. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263(Suppl 2):S155–S168.
63.
CalvoAMorenoMRuiz-SanchoA. Intervention for adolescents with early onset psychosis and their families: a randomized control trial. J Am Acad Child Adolesc Psychiatry. 2014;53(6):688–696.
64.
CaseiroOPérez-IglesiasRMataI. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099–1105.
65.
WiersmaDNienhuisFJSlooffCJ. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75–85.
66.
StephensonJ. Delay in treating schizophrenia may narrow therapeutic window of opportunity. JAMA. 2000;283(16):2091–2092.
67.
HoBCAndreasenNCNopoulosP. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60(6):585–594.
68.
McGorryPDKillackeyEYungA. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148–156.
69.
BirchwoodMToddPJacksonC. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53–59.
70.
Alvarez-JimenezMParkerAGHetrickSE. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37(3):619–630.
71.
DeshmukhPKulkarniGBarzmanD. Recommendations for pharmacological management of inpatient aggression in children and adolescents. Psychiatry (Edgmont). 2010;7(2):32–40.
72.
HiltRJWoodwardTA. Agitation treatment for pediatric emergency patients. J Am Acad Child Adolesc Psychiatry. 2008;47(2):132–138.
73.
SteinerHSaxenaKChangK. Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr. 2003;8(4):298–308.
74.
CorrellCU. Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health. 2009;12(3):93.
75.
DeanAJMcDermottBMMarshallRT. PRN sedation-patterns of prescribing, administration in a child, adolescent mental health inpatient service. Eur Child Adolesc Psychiatry. 2006;15(5):277–281.
76.
PringsheimTPanagiotopoulosCDavidsonJ. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health. 2011;16(9):581–589.
77.
SchneiderCCorrigallRHayesD. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29(1):1–10.
78.
CitromeL. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545–1573.
79.
ShawPSpornAGogtayN. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63(7):721–730.
80.
KumraSKranzlerHGerbino-RosenG. Clozapine and ‘high-dose’ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524–529.
81.
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. Clinical guideline number178. 2014. [Cited 2017 February 10]. Available fromhttps://www.nice.org.uk/guidance/cg178
82.
National Institute for Health and Care Excellence. Psychosis with coexisting substance misuse: assessment and management in adults and young people. Clinical guideline number120. 2011. [Cited 2017 February 10]. Available fromhttps://www.nice.org.uk/guidance/cg120
83.
Scottish Intercollegiate Guidelines Network. Management of schizophrenia. SIGN publication number 131. Edinburgh (GB): Scottish Intercollegiate Guidelines Network; 2013.
84.
SchmidtSJSchultze-LutterFSchimmelmanBG. EPA guidance on early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):388–404.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
